Alan Feldman, DO
Family Medicine · Commerce Twp, MINPI 1760448179
Payments from drug & device makers
Across 92 payments — averaging $17.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$487
- Boehringer Ingelheim$317
- GSK$157
- Exact Sciences$91
- Pfizer$59
- Novartis$54
- plus $459 from 21 others
What the payments were for
- Food & beverage$1,624100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 28 | $487 |
| Boehringer Ingelheim | 17 | $317 |
| GSK | 9 | $157 |
| Exact Sciences | 5 | $91 |
| Pfizer | 3 | $59 |
| Novartis | 4 | $54 |
| Amgen(2 entities) | 3 | $54 |
| Boston Scientific | 2 | $45 |
| Novo Nordisk | 2 | $34 |
| Teva Pharmaceuticals USA, Inc. | 1 | $34 |
| AbbVie | 2 | $29 |
| Abbott | 1 | $28 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $27 |
| Eisai Inc. | 1 | $25 |
| Actelion Pharmaceuticals US, Inc. | 1 | $17 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $16 |
| Melinta Therapeutics, LLC | 1 | $15 |
| Otsuka America Pharmaceutical, Inc. | 1 | $15 |
| Paratek Pharmaceuticals, Inc. | 1 | $15 |
| Viatris Specialty LLC | 1 | $14 |
| Organogenesis Inc. | 1 | $14 |
| Lilly USA, LLC | 1 | $14 |
| Dexcom, Inc. | 1 | $13 |
| Biodelivery Sciences International, Inc. | 1 | $13 |
| Hikma Pharmaceuticals USA | 1 | $13 |
| Kowa Pharmaceuticals America, Inc. | 1 | $13 |
| Amarin Pharma, Inc. | 1 | $12 |
How this compares
$1,624 in reported general payments places this provider in the 75th percentile of 3,945 family medicine providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 54 | $54,297 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 68 | $49,193 |
| EliquisApixaban | 32 | $42,509 |
| JardianceEmpagliflozin | 30 | $36,645 |
| Spiriva RespimatTiotropium Bromide | 35 | $25,120 |
| JanuviaSitagliptin Phosphate | 16 | $17,165 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 16 | $11,197 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 12 | $5,608 |
| MyrbetriqMirabegron | 11 | $4,763 |
| SymbicortBudesonide/Formoterol Fumarate | 18 | $4,234 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 94 | $3,758 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 25 | $3,328 |
| Atorvastatin Calcium | 277 | $3,319 |
| Montelukast Sodium | 161 | $3,039 |
| Gabapentin | 227 | $2,925 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Spiriva Respimat, Stiolto Respimat | $317 | $72,96281 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $157 | $54,80180 claims |
| Novo NordiskOzempic | $34 | $54,29754 claims |
| PfizerEliquis | $59 | $42,50932 claims |
| AstraZenecaSymbicort | $487 | $4,23418 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 3,945 family medicine providers in Michigan.
Other family medicine in Commerce Twp
- Derrick WilliamsonSouthfield$9.9M
- Rebecca RivardRoseville$7M
- Paul BensonBerkley$4.2M
- Michael HafranEast Lansing$2.7M
- Mitzie HewittBuckley$1.3M
- Loren ChudlerSouthfield$1.3M
- Solomon AmsterWhite Lake$981K
- Matt RosenbergJackson$559K
- Rhonda MejeurGrand Rapids$493K
- Steve LasaterSaint Johns$291K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.